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Chikungunya virus (CHIKV) is a mosquito-borne al-
phavirus best known for causing fever, rash, arthralgia, and 
occasional neurologic disease. By using real-time reverse 
transcription–PCR, we detected CHIKV in plasma samples 
of 8 (14%) of 58 children with suspected central nervous 
system infection in Bellary, India. CHIKV was also detected 
in the cerebrospinal ﬂ  uid of 3 children.
C
hikungunya virus (CHIKV) is a mosquito-borne al-
phavirus that causes illness characterized by fever, 
rash, and severe arthralgia. It was ﬁ  rst described in Africa 
in 1952, and outbreaks occurred in India in the 1960s and 
early 1970s (1). Neurologic complications were reported 
occasionally (2,3). In 2005, an epidemic of CHIKV dis-
ease occurred among the populations of Réunion and other 
Indian Ocean islands (1,4), and spread to India by early 
2006, where an estimated 1.3 million persons were infected 
(5,6). During a prospective study of all children with sus-
pected central nervous system (CNS) infections admitted to 
a hospital in rural southern India, we noticed an unseasonal 
increase in admissions. This increase occurred at the same 
time as the CHIKV outbreak in southern India, so we in-
vestigated our cohort for CHIKV infection.
The Study
From January through October 2006, we studied chil-
dren (<16 years of age) admitted to the pediatric department 
of the Vijayanagar Institute of Medical Sciences, Bellary, 
India, with suspected acute CNS infection. Acute CNS in-
fections were suspected in those children with a febrile 
illness (<2 weeks’ duration) and 1 of the following signs 
or symptoms: meningism, photophobia, severe headache, 
altered mental status, seizures, or focal neurologic signs. 
Children with previous neurologic conditions or Plasmo-
dium falciparum malaria were excluded. The study was ap-
proved by the ethical committees of the hospital, the Indian 
Council for Medical Research, and the University of Liv-
erpool, United Kingdom. Informed consent was obtained 
from the accompanying parent or guardian.
A detailed history was taken, and a neurologic exami-
nation was performed by a member of the study team. Rou-
tine blood samples were collected, and a lumbar puncture 
was performed. To detect CHIKV RNA in the plasma or 
cerebrospinal ﬂ  uid (CSF), real-time reverse transcription–
PCR for a 127-base region of the envelope E1 gene was 
performed (7). The E1 gene was subsequently ampliﬁ  ed by 
RT-PCR, and sequenced (7). A 529-base region of the se-
quence was aligned with other CHIKV E1 gene sequences 
by using Lasergene software (DNASTAR, Inc., Madison, 
WI, USA), and phylogenetic analysis was performed on 
the align sequences by using Mega 4 software (8). To de-
tect antibodies against Japanese encephalitis (JE) virus and 
dengue virus, which circulate in this area, serum specimens 
and CSF were tested by immunoglobulin M (IgM) capture 
ELISA (9). PCR for JE virus was also performed on CSF 
samples (10).
From January 1 through October 31, 2006, 66 children 
were recruited for the study; 37 (56%) were male, median 
age was 7 years (range 8 months–16 years ); 58 had at least 
1 plasma sample, and 57 had a CSF sample available for 
testing. CHIKV was detected in 8 (14%) of the 58 plasma 
samples and in 3 (5%) of the CSF samples; CHIKV was 
not detected in 2 CSF samples, and no CSF samples were 
available for 3 children. The median (range 2–23) of days 
for a positive plasma sample was 3.5 days; the 3 positive 
CSF samples were all obtained within 4 days of illness on-
set (online Appendix Table, available from www.cdc.gov/
EID/content/15/2/329-appT.htm). Samples from all 8 pa-
tients were negative for malaria parasites and JE and den-
gue IgM antibodies. We also tested samples obtained be-
fore the outbreak (October 2005 through December 2005) 
and after the outbreak (November 2006 through December 
2007); all were CHIKV negative.
Of the CHIKV-positive children, 7 children had al-
tered mental status, which was associated with seizures in 6 
patients; 3 children with both altered mental status and sei-
zures also had meningism. Two children had a rash when 
they were hospitalized, and a rash developed in a third child 
on day 5 of hospitalization. Seven children had seizures and 
4 had status epilepticus (seizure >30 min). Three children 
were aphasic and had extensor plantar reﬂ  exes. One 9-year-
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iting, and a generalized tonic-clonic seizure at home that 
lasted 3 minutes; this occurred 3 days after she received a 
live attenuated SA14-14-2 JE vaccine. When hospitalized, 
she had a score of 15 on the Glasgow Coma Scale (GCS) 
and was monitored without a lumbar puncture. CHIKV was 
detected in her plasma. Only 2 of the 5 patients whose CSF 
was analyzed had pleocytosis (>5 cells × 109/mL). Two 
children had reduced GCS scores, and 1 child remained 
aphasic when discharged. The other 6 patients were dis-
charged with a full GCS score. At her 4-month follow-up 
visit, patient 8, who had CHIKV detected in her CSF and 
plasma, was performing poorly at school and had back and 
joint aches. 
An 8-month-old girl (patient 7) was admitted who had 
experienced a fever for 7 days, multiple seizures, a wide-
spread rash, and loss of appetite. She also had reduced 
hearing, a GCS score of 13, a vacant stare, frequent blink-
ing, hepatomegaly (4 cm), and splenomegaly (6 cm). While 
she was an inpatient, gangrene developed in her ﬁ  ngers and 
toes (Figure 1). Her initial plasma and CSF samples were 
all used for clinical management, but a subsequent plasma 
sample was positive for CHIKV on day 23 of illness.
E1 gene PCR products sufﬁ  cient for sequencing were 
ampliﬁ  ed from plasma samples of 5 patients and the CSF 
of 1 patient. Sequences were deposited in GenBank under 
accession nos. EU856107–EU856112. Sequences were 
identical except for one that had a single nucleotide change 
from A to G at position 10625, resulting in an amino acid 
change from lysine to arginine at residue 211 of the E1 
protein. The sequences from our cohort all had an alanine 
residue at position 226 of the E1 protein. This ﬁ  nding is 
typical of 90% of viral sequences from the Réuinion Is-
lands from June 2005 through October 2005 (11). Isolates 
from the Réunion Island outbreak all had a valine at this 
position (11). Scientists have postulated that the change at 
E1–A226V may be important for adaption to the mosquito 
vector, Aedes albopictus, and for neurovirulence (11–13). 
Our isolates lack this substitution. Phylogenetic analysis 
showed that the viruses were more closely related to those 
from the recent Indian Ocean CHIKV outbreaks and East 
African strains than to the Asian strains endemic in the re-
gion (Figure 2).
Conclusions
Our study has conﬁ  rmed that during a CHIKV out-
break, the virus may be an important cause of neurologic 
disorders in children. Recent studies have described a wide 
range of neurologic manifestations, including meningoen-
cephalitis, seizures, and Guillain-Barré syndrome (14–16). 
Our study shows that CHIKV is a likely cause of CNS 
infection. During the outbreak period from January 2006 
through October 2006, we found that CHIKV was respon-
sible for 14% of suspected CNS infections. In 1 of our pa-
tients, an 8-month-old girl for whom no acute-phase sample 
was available, the virus was detected at day 23 of illness, 
an unusually persistent level of viremia. The severity of her 
illness, with marked rash, hepatosplenomgaly, and digital 
gangrene could have been due to her inability to clear the 
virus. Alternatively, she may have become infected with 
CHIKV during her hospital stay. If one excludes this pa-
tient from the analysis, CHIKV was detected in the plasma 
and CSF samples of 10% of patients with suspected CNS 
infection. Some children had other features suggestive of 
CHIKV infection, but in 4 case-patients, only neurologic 
symptoms were present. Notably, 1 child had received JE 
vaccine 3 days before admission as part of a mass JE vacci-
nation campaign in India (17). Her illness was attributed to 
an adverse event after vaccination (18). We demonstrated 
that her illness was equally coincident with CHIKV infec-
tion, illustrating the importance of thorough investigation 
of cases of adverse events after vaccination.
In our study, we chose to rely on PCR detection of 
the virus to diagnose CHIKV infection rather than testing 
for IgM antibodies, which may persist for several months 
after infection and could reﬂ  ect coincidental infection (19) 
rather than an acute infection. In summary, during CHIKV 
outbreaks, clinicians should be aware that CHIKV may be 
a cause of CNS infections among children.
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Figure 1. Digital gangrene in an 8-month-old girl during week 3 of hospitalization. She was admitted to the hospital with fever, multiple 
seizures, and a widespread rash; chikungunya virus was detected in her plasma. A) Little ﬁ  nger of the left hand; B) index ﬁ  nger of the right 
hand; and C) 4 toes on the right foot. Chikungunya Virus in Children, India
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Figure 2. Phylogenetic analysis of chikungunya virus (CHIKV)
sequences on the basis of partial E1 gene sequence (position 
10620–11148 of the prototype CHIKV S27 genomic sequence). 
Sequences obtained in this study are in boldface. The analysis 
was performed using MEGA version 4 software (8), by using 
the neighbor-joining (p-distance) method. The length of the tree 
branches indicates the percentage of divergence; the percentage 
of successful bootstrap replicates is speciﬁ  ed at the nodes (1,000 
replicates). ONNV (o’nyong-nyong virus) prototype sequence was 
included to root the tree. Scale bar indicates number of nucleotide 
substitutions per site.